PARP1 and breast carcinoma: In human breast cancer cell line MB-231 tumor-bearing mice, the combination of PARP inhibitor and EZH2 inhibitor or the simultaneous knockdown of PARP and EZH2 promoted the polarization of tumor-associated macrophages (TAMs) toward M2 and the generation of neovascularization in tumors (Yang et al., 2020).